Biosimilars : the perception amongst Maltese clinicians

Abstract

A poster presentation regarding the perception amongst Maltese clinicians on biosimilars. Introduction: A biosimilar product is biologic in origin. It is highly similar to another biological medicinal product (reference product), which has already been authorised by a competent regulatory authority such as the European Medicines Agency. It must have no clinically meaningful difference in terms of safety, purity and potency when compared to the reference product. The availability of biosimilar infliximab on the National Health System in Malta introduced issues related to safety, switchability and interchangeability. Aims: • To assess the perception and awareness of Maltese clinicians working within the National Health System on the concept of biosimilars.